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Introduction {#brb3453-sec-0006}
============

Levodopa is the gold standard symptomatic treatment in Parkinson′s disease (PD), although its long‐term use is associated with the development of motor complications. Alternatively, dopamine agonists (DAs) have shown to be effective, both as monotherapy in the early stages of PD or in association with levodopa in advanced PD (Antonini et al. [2009](#brb3453-bib-0001){ref-type="ref"}). However, DAs are associated with a greater risk of developing dopaminergic side effects (somnolence, hallucinations, edema, impulse control disorders, etc.) compared with levodopa, and their use is avoided in the elderly for reasons including altered drug metabolism, an increased risk of adverse effects, increased comorbid conditions, increased risk of drug interactions, and a higher risk of cognitive problems and behavior disorders in PD patients over the age of 70 years (Kempster et al. [2007](#brb3453-bib-0008){ref-type="ref"}; Stowe et al. [2008](#brb3453-bib-0020){ref-type="ref"}). However, there is no compelling evidence for such concerns because few elderly PD patients have been enrolled in clinical trials (Mitchell et al. [1997](#brb3453-bib-0010){ref-type="ref"}). Moreover, a previous study demonstrated that trials with DAs are warranted in selected very elderly patients (Shulman et al. [2000](#brb3453-bib-0018){ref-type="ref"}).

The aims of this study were as follows: (1) to determine the reasons of DA withdrawal (DAW) in a group of PD patients in clinical practice; and (2) to identify the predictive factors of DAW. Specifically, we studied the effect of age, comorbidity, and polypharmacy as potential risk factors for DAW.

Materials and Methods {#brb3453-sec-0007}
=====================

We conducted a retrospective chart review of the follow‐up of a subgroup of nondemented PD patients receiving a DA (*n* = 68; 60.3% males, 69.3 ± 9.2 years old) from a cohort (*n* = 150) previously studied in detail (Santos‐García and de la Fuente‐Fernández [2013](#brb3453-bib-0015){ref-type="ref"}, [2015](#brb3453-bib-0016){ref-type="ref"}). The patients from the cohort who were receiving a DA, such as pramipexole, ropinirole, and rotigotine at baseline (cross‐sectional study conducted in 2012) were included in this study. Figure [1](#brb3453-fig-0001){ref-type="fig"} shows a flowchart of the selection and inclusion of patients. Baseline assessment included motor dysfunction (ON‐state Hoehn & Yahr \[H&Y\] / Unified Parkinson\'s Disease Rating Scale \[UPDRS\] part III and motor complications \[UPDRS part IV\]), mood (Beck Depression Inventory \[BDI\]), nonmotor symptoms (Nonmotor Symptoms Scale \[NMSS\]), disability (Schwab & England Activities of Daily Living Scale \[ADLS\]), socio‐demographic variables, and other disease‐related variables.

![Flowchart of inclusion in the clinical practice cohort. ADLS, Activities of Daily Living Score; BDI, Beck Depression Inventory; COMTI, catechol‐O‐methyl transferase inhibitor; DA, dopamine agonist; DAW, dopamine agonist withdrawal; MAOBI, monoamine oxidase B inhibitor; MSA, multiple system atrophy; NMSS, Nonmotor Symptoms Scale; UPDRS, Unified Parkinson\'s Disease Rating Scale (part III, motor examination; part IV, motor complications). \*Data are from 149 patients because one case was diagnosed with MSA "a posteriori".](BRB3-6-e00453-g001){#brb3453-fig-0001}

The follow‐up information was collected from medical records by a neurology resident (E.S.C.). The follow‐up period was from the baseline evaluation (between 11 May and 24 December 2012 depending on the case) to 23 March 2015. The reason for DAW, age at DAW, follow‐up time, time until DAW (time from baseline to DA withdrawal), time taking DA therapy (time taking the DA before baseline) and DA dose (Tomlinson et al. [2010](#brb3453-bib-0021){ref-type="ref"}) changes were collected. The study (CADAW‐PD, Causes and fActors related to Dopamine Agonist Withdrawal in Parkinson′s Disease; DIE‐LEV‐2015‐01) was approved by the local ethics committee. All participants signed an informed consent form.

Data were processed using SPSS 21.0 for Windows. Proportions between groups were compared using the chi‐square test. Continuous variables are expressed as the mean ± SD or median and quartiles, depending on whether they were normally distributed and were compared using the Student′s *t* test or the Mann--Whitney test, as appropriate. We defined two groups relative to the primary endpoint (DA withdrawal): (1) patients who discontinued DA therapy during follow‐up (DAW group); and (2) patients who did not discontinue DA therapy (non‐DAW group). Univariate and multiple regression analyses were performed to evaluate predictors of DAW. Specifically, we studied the effect of age, comorbidity, and polypharmacy as potential risk factors for DAW. The number of drugs different of antiparkinsonian agents taken at baseline was considered a surrogate marker of comorbidity. Polypharmacy was assessed by counting the total number of pills at baseline. Values of p \< 0.05 were considered significant.

Results {#brb3453-sec-0008}
=======

Sixty‐eight PD patients from the cohort (*n* = 150) (Santos‐García and de la Fuente‐Fernández [2013](#brb3453-bib-0015){ref-type="ref"}, [2015](#brb3453-bib-0016){ref-type="ref"}) were receiving DA therapy at baseline: 30 pramipexole, 20 rotigotine, 17 ropinirole, and one pramipexole + rotigotine. Seven patients died and two cases (taking ropinirole) were lost to follow‐up. Twelve of 66 patients (18.2%) discontinued DA therapy during follow‐up (690.2 ± 232.6 days; range, 128--1080). Figure [2](#brb3453-fig-0002){ref-type="fig"} shows the frequency of DAW according to DA therapy and the patients\' medications at baseline. The reasons for DAW are shown in Table [1](#brb3453-tbl-0001){ref-type="table-wrap"}.

![Percentage of patients taking DA therapy (pramipexole, rotigotine and/or ropinirole) at baseline (top bar) and at the end of follow‐up (bottom bar). Cases who discontinued DA therapy are indicated by a dark color in the bottom bar. The DAW percentage was 10% for pramipexole (3/30), 20% for rotigotine (4/20), 26.7% for ropinirole (4/15) and for the only case taking pramipexole + rotigotine. At the end of the follow‐up, 54 patients were receiving DA therapy: 50% pramipexole (27/54), 29.6% rotigotine (16/54) and 20.4% ropinirole (11/54). DA, dopamine agonist.](BRB3-6-e00453-g002){#brb3453-fig-0002}

###### 

Reasons of DAW considering different type of DA therapy. "Time until DAW" refers to time from baseline to DA withdrawal. "Time taking DA therapy" refers to time taking the DA before baseline

  DA Therapy                                    Reasons of DAW    Time until DAW (days)   Age at DAW    Time taking DA therapy (days)
  --------------------------------------------- ----------------- ----------------------- ------------- -------------------------------
  Pramipexole (*n* = 30)                        3 cases (10%)     437.7 ± 476.2           71.3 ± 7      1250.3 ± 724.8
  Case 1 simplification of treatment (DBS)      12                64                      1987          
  Case 2 diurnal somnolence                     349               78                      1226          
  Case 3 starting with levodopa enteral         882               72                      538           
  Rotigotine (*n* = 20)                         4 cases (20%)     511.7 ± 333.9           68.8 ± 6.3    548.2 ± 563.3
  Case 1 cognitive impairment ‐\> dementia      112               66                      48            
  Case 2 skin reaction and diurnal somnolence   644               67                      155           
  Case 3 cognitive impairment ‐\> dementia      719               78                      723           
  Case 4 visual hallucinations                  846               64                      1267          
  Ropinirole (*n* = 15)                         4 cases (26.7%)   503 ± 118.2             60.3 ± 11.7   1295.5 ± 1052.2
  Case 1 visual hallucinations                  385               62                      1232          
  Case 2 dyskinesia                             429               63                      2689          
  Case 3 simplification of treatment            554               72                      1126          
  Case 4 dyskinesia/dystonia (ON)               644               44                      135           
  Pramipexol + rotigotine (*n* = 1)             1 case (100%)     551                     70            1815
  Cognitive impairment ‐\> dementia                                                                     

DA, dopamine agonist; DBS, deep brain stimulation; DAW, dopamine agonist withdrawal.
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As shown in Table [2](#brb3453-tbl-0002){ref-type="table-wrap"}, an earlier age at PD onset, a longer disease duration, a higher daily dose of levodopa, a greater number of pills for PD, polypharmacy, and a higher number of nonmotor symptoms were associated with DAW. However, age was not related to DAW. In fact, only one patient discontinued DA therapy in the subgroup of patients over the age of 75 years old (Fig. [3](#brb3453-fig-0003){ref-type="fig"}). On the contrary, mortality was significantly higher in this group of patients.

###### 

Factors related (at baseline) to DAW (*n* = 12) versus non‐DAW (*n* = 54)

                                        Non‐DAW (*n* = 54)   DAW (*n* = 12)   *P*
  ------------------------------------- -------------------- ---------------- -----------
  Age                                   70.3 ± 9.1           65.3 ± 8.8       0.092
  Males (%)                             63                   58.3             0.505
  Age of symptoms onset                 63.5 ± 7.9           54.8 ± 13.1      **0.004**
  Disease durarion (years)              7.3 ± 3.9            10.6 ± 8.4       **0.040**
  Hoehn&Yahr (ON)                       2 \[2, 2.5\]         2 \[1.6, 2\]     0.171
  UPDRS‐III (ON)                        15.3 ± 7.6           15.4 ± 9.5       0.974
  UPDRS‐IV                              3.1 ± 2.7            4.3 ± 2.7        0.176
  Motor fluctuations (%)                38.9                 50               0.347
  Dyskinesia (%)                        40.7                 58.3             0.215
  Levodopa (%)                          85.2                 100              0.181
  COMT‐inhibitor (%)                    53.7                 25               0.068
  MAO B inhibitor (%)                   33.3                 25               0.425
  Time taking DA therapy (days)         1288.3 ± 805.7       1078.4 ± 812.6   0.419
  Levodopa daily dose (mg)              490.7 ± 321.1        820.8 ± 520.7    **0.006**
  DA equivalent daily dose (mg)         246.6 ± 117.1        253.8 ± 179.2    0.864
  Levodopa equivalent daily dose (mg)   795.2 ± 432          1089.2 ± 641.7   0.064
  Comorbidity                           4.1 ± 2.6            4 ± 2.6          0.896
  Total number of pills for PD          5.6 ± 2.6            7.7 ± 3.6        **0.019**
  Polypharmacy                          9.4 ± 3.4            12 ± 4.4         **0.028**
  NMSS total score (0--360)             65.5 ± 54.1          90.8 ± 58.3      0.154
  NMSS domains 2+3+4                    26.2 ± 25.6          34.9 ± 26        0.293
  Number of nonmotor symptoms           14.9 ± 5.7           19.3 ± 6.3       **0.022**
  BDI (0--63)                           11.9 ± 7.6           15.1 ± 9         0.214
  ADLS (0--100)                         80 \[60, 90\]        65 \[35, 80\]    0.112

ADLS, Activities of Daily Living Score; BDI, Beck Depression Inventory; COMT, catechol‐O‐methyl transferase; DA, dopamine agonist; DAW, dopamine agonist withdrawal; MAO, monoamine oxidase; NMSS, Nonmotor Symptoms Scale; UPDRS, Unified Parkinson\'s Disease Rating Scale (part III, motor examination; part IV, motor complications).

Bold values: Results are expressed as mean ± SD or %.
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![DAW, deaths and follow‐up time in the subgroups of PD patients in relation to age: 1) ≤65 years (5 DAW cases); 2) 66--75 years (6 DAW cases and 1 death); 3) \>75 years (DAW in only 1 case and 6 deaths). DAW, dopamine agonist withdrawal.](BRB3-6-e00453-g003){#brb3453-fig-0003}

Cox‐regression analysis showed that only the levodopa daily dose was a predictor of DAW. Table [3](#brb3453-tbl-0003){ref-type="table-wrap"} shows different models in which DAW was the dependent variable and levodopa daily dose, comorbidity, polypharmacy, socio‐demographic patient‐related variables (age and gender), disease‐related variables (disease duration, age of symptoms onset, ON‐H&Y, ON‐UPDRS‐III, UPDRS‐IV, NMSS total score), and confounder variables (time taking DA therapy and follow‐up time) were independent variables. The nonadjusted hazard ratio (HR) of the levodopa daily dose for DAW was 1.002 (95% confidence interval \[CI\], 1.001--1.003; *P* = 0.006). The levodopa daily dose HR was 1.003 (95% CI, 1.001--1.006; *P* = 0.044) after adjustment for covariates. As expected, when PD patients were classified according to the levodopa daily dose, a significantly higher percentage of DAW was observed in those receiving more than 750 mg per day (42.8% vs. 11.5%; *P* = 0.014) (Table [4](#brb3453-tbl-0004){ref-type="table-wrap"}).

###### 

Analysis of the factors predicting dopamine agonist withdrawal

  Parameter                                                      Univariate (HR; 95% CI; *P*‐value)   Multivariate Cox regression[3](#brb3453-note-0006){ref-type="fn"} (HR; 95% CI; *P*‐value)   Multivariate Cox regression[4](#brb3453-note-0007){ref-type="fn"} (HR; 95% CI; *P*‐value)   Multivariate Cox regression[5](#brb3453-note-0008){ref-type="fn"} (HR; 95% CI; *P*‐value)
  -------------------------------------------------------------- ------------------------------------ ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------
  Levodopa daily dose[1](#brb3453-note-0004){ref-type="fn"}      1.002; 1.001--1.003; **0.006**       1.002; 1.001--1.003; **0.001**                                                              1.002; 1.001--1.004; **0.019**                                                              1.003; 1.001--1.006; **0.044**
  Age[1](#brb3453-note-0004){ref-type="fn"}                                                           0.935; 0.883--0.991; **0.023**                                                              1.331; 0.541--3.278; 0.534                                                                  2.211; 0.561--8.707; 0.257
  Gender                                                                                              0.830; 0.261--2.644; 0.275                                                                  0.831; 0.247--2.797; 0.765                                                                  0.241; 0.038--1.516; 0.129
  Age at symptoms onset[1](#brb3453-note-0004){ref-type="fn"}                                                                                                                                     0.703; 0.282--1.755; 0.450                                                                  0.412; 0.102--1.667; 0.214
  Disease duration[1](#brb3453-note-0004){ref-type="fn"}                                                                                                                                          0.696; 0.274--1.765; 0.445                                                                  0.411; 0.102--1.654; 0.211
  Time taking DA therapy[1](#brb3453-note-0004){ref-type="fn"}                                                                                                                                    1.000; 0.999--1.001; 0.631                                                                  0.999; 0.998--1.001; 0.364
  Follow‐up time[1](#brb3453-note-0004){ref-type="fn"}                                                                                                                                            1.000; 0.997--1.003; 0.927                                                                  1.000; 0.995--1.004; 0.846
  Comorbidity[1](#brb3453-note-0004){ref-type="fn"}                                                                                                                                                                                                                                           1.040; 0.680--1.592; 0.856
  Polypharmacy[1](#brb3453-note-0004){ref-type="fn"}                                                                                                                                                                                                                                          1.243; 0.929--1.663; 0.143

^1^Hazard ratio is the risk multiplier per unit increase in the parameter.

^2^Figures in bold are statistically significant (*P* \< 0.005).

^3^Variables entered: levodopa daily dose, age and gender.

^4^Variables entered: levodopa daily dose, age, gender, age at diagnosis, disease duration, time taking DA therapy and follow‐up time.

^5^Variables entered: levodopa daily dose, age, gender, age at diagnosis, disease duration, time taking DA therapy, follow‐up time, comorbidity, polypharmacy, and other covariates (ON‐H&Y, ON‐UPRDS‐III, UPDRS‐IV, NMSS total score).
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###### 

Percentage of patients who presented dopamine agonist withdrawal (DAW) according to levodopa daily dose (\>750 mg vs. ≤750 mg): 42.9% (6/14) vs. 11.5% (6/52); *P* = 0.014

            Levodopa dose ≤ 750 mg/day   Levodopa dose \> 750 mg/day   Number of patients
  --------- ---------------------------- ----------------------------- --------------------
  Non DAW   46 (88.5%)                   8 (57.1%)                     54
  DAW       6 (**11.5%**)                6 (**42.9%**)                 12
            52                           14                            66

Bold values: Results are expressed as number of patients and %.
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Discussion {#brb3453-sec-0009}
==========

There is considerable controversy regarding the use of DAs in the elderly because of the concern for a higher rate of side effects. However, there is no evidence for such concerns because few individuals older than 75 years have been enrolled in clinical trials for antiparkinsonian medications (Mitchell et al. [1997](#brb3453-bib-0010){ref-type="ref"}; Fitzsimmons et al. [2012](#brb3453-bib-0006){ref-type="ref"}). Our study demonstrates that an advanced age alone is not a contraindication for the administration of DA therapy. In PD, therapeutic decisions should be individualized, and we must keep in mind that the risk of DAW is higher when DA therapy is administered to PD patients with a longer disease duration, polypharmacy, and a higher daily dose of levodopa.

Clinical--pathological studies have demonstrated that cognitive disability, visual hallucinations, or residential care is more frequent in PD patients over the age of 70 years (Kempster et al. [2007](#brb3453-bib-0008){ref-type="ref"}). In addition, older patients metabolize drugs differently than younger patients and may be more susceptible to drug side effects, which are often complicated by comorbid conditions (Robertson et al. [1989](#brb3453-bib-0014){ref-type="ref"}). For these reasons, DAs historically have been avoided by some clinicians as therapy in elderly patients. However, Shulman et al. ([2000](#brb3453-bib-0018){ref-type="ref"}) reported that DAs were well tolerated by very elderly (≥80 years old) and appropriately selected PD patients in clinical practice. In our study, about half of the PD patients were early elderly (from 65 to 74 years old) and a quarter were late elderly (over 75 years old). Furthermore, Oertel et al. ([2013](#brb3453-bib-0012){ref-type="ref"}) observed that rotigotine was generally well tolerated regardless of age. Our results are in line with these studies.

Treatment considerations for elderly PD patients typically have centered on chronological age, and somewhat arbitrary cutoffs have been established for determining whether DA therapy should be used. However, patients with similar chronological ages may differ substantially with respect to functional or physiological age. Functional age can be assessed by measuring motor and nonmotor symptoms, including cognition, mood, behavior, disability, comorbidity, and other dimensions that contribute to functionality. When considering functional age in treatment planning, the clinician can appreciate variability among patients of the same age (Silver [2006](#brb3453-bib-0019){ref-type="ref"}). Our results support this idea. The risk of DAW seems to be higher in PD patients with longer disease duration, polypharmacy and more nonmotor symptoms. Indeed, levodopa dosage determines the probability of DAW, with a thirty percent higher risk for every increase in 1.000 mg of levodopa. In other words, almost half of the patients receiving more than 750 mg per day of levodopa discontinued with DA therapy versus one in ten of patients receiving a smaller dose. Related to this finding, compliance with once‐daily DA therapy has been reported to be suboptimal and to depend upon the total daily dose of levodopa and the total number of daily drugs (Santos‐García et al. [2012](#brb3453-bib-0017){ref-type="ref"}). Although comorbidity is a risk factor for the development of somnolence, edema, or hallucinations in PD patients (Biglan et al. [2007](#brb3453-bib-0005){ref-type="ref"}), these conditions were not related to DAW in our study. No statistical determinants for the discontinuation of DAs were detected in other studies (Arbouw et al. [2008](#brb3453-bib-0003){ref-type="ref"}).

Overall, our findings suggest that DA therapy is well tolerated in properly selected PD patients in clinical practice. The number of patients who discontinued DA therapy in our series was low. In fact, DAW in three cases was not due to adverse events. Moreover, adverse events in three other cases were in the context of cognitive impairment progressing to dementia. Previous observational studies have largely focused on discontinuation rates for DAs introduced as a supplement to levodopa (Hauser et al. [2007](#brb3453-bib-0007){ref-type="ref"}; Arbouw et al. [2008](#brb3453-bib-0003){ref-type="ref"}, [2009](#brb3453-bib-0004){ref-type="ref"}; Parkinson Study Group [2009](#brb3453-bib-0013){ref-type="ref"}; Valldeoriola et al. [2009](#brb3453-bib-0022){ref-type="ref"}; Nissen et al. [2012](#brb3453-bib-0011){ref-type="ref"}). A maintenance of pramipexole in approximately 80% at 6 years (Parkinson Study Group [2009](#brb3453-bib-0013){ref-type="ref"}) and 90% between 5 and 10 years for ropinirole (Hauser et al. [2007](#brb3453-bib-0007){ref-type="ref"}) has been reported in extended open‐label observational studies. Future studies are needed to know the extent to which PD patients tolerate different DAs according to age (Oertel et al. [2013](#brb3453-bib-0012){ref-type="ref"}), and interestingly, the AD type (Kim et al. [2015](#brb3453-bib-0009){ref-type="ref"}) and genetic determinants (Arbouw et al. [2007](#brb3453-bib-0002){ref-type="ref"}).

This study has several limitations. First, the sample size was small, and as result, some differences between groups might have been insignificant. Second, death is a confounding factor because there were more cases in older patients, and follow‐up time was significantly shorter in older patients. However, the follow‐up time was included as a covariate in the model. Third, we used a surrogate marker of comorbidity, but we think that, in any case, it provides proper information on the variable (a larger number of drugs different of antiparkinsonian agents indicates more frequent and/or severe comorbidity). Fourth, some information may have been missed due to the methodology used (chart review). However, the findings are novel and have practical applicability in clinical practice. Fifth, a cognition assessment using a specific scale at baseline was not conducted. Finally, follow‐up information on adverse events was not collected in patients who continued receiving DA therapy at the end of the follow‐up. Nevertheless, this study was not designed to evaluate tolerability and effectiveness. Thus, we can assume that patients continued taking the medication in clinical practice because it is useful and well tolerated.

In conclusion, our study shows that DA therapy is generally well tolerated by nondemented PD patients in clinical practice. Advanced age alone is not a contraindication to the administration of DA therapy. We must keep in mind that the probability of successful treatment when we use DA therapy is lower in PD patients with a longer disease duration, polypharmacy, and a higher daily dose of levodopa.
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